Portola Pharmaceuticals Inc (PTLA) Forecasted to Earn Q1 2018 Earnings of ($1.72) Per Share
Portola Pharmaceuticals Inc (NASDAQ:PTLA) – Equities research analysts at Oppenheimer issued their Q1 2018 EPS estimates for Portola Pharmaceuticals in a research note issued on Thursday. Oppenheimer analyst J. Olson anticipates that the biopharmaceutical company will post earnings of ($1.72) per share for the quarter. Oppenheimer has a “Buy” rating and a $67.00 price objective on the stock. Oppenheimer also issued estimates for Portola Pharmaceuticals’ Q2 2018 earnings at ($0.32) EPS, Q3 2018 earnings at ($1.61) EPS, Q4 2018 earnings at ($1.48) EPS, FY2018 earnings at ($5.00) EPS and FY2019 earnings at ($0.51) EPS.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.46) by $0.05. Portola Pharmaceuticals had a negative net margin of 1,268.34% and a negative return on equity of 121.61%. The company had revenue of $9.80 million for the quarter, compared to the consensus estimate of $3.71 million. During the same quarter in the prior year, the company earned ($0.95) EPS. Portola Pharmaceuticals’s quarterly revenue was down 28.4% on a year-over-year basis.
Portola Pharmaceuticals (NASDAQ PTLA) opened at $34.25 on Monday. Portola Pharmaceuticals has a fifty-two week low of $30.10 and a fifty-two week high of $67.10. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.31 and a quick ratio of 8.31. The firm has a market cap of $2,230.00, a P/E ratio of -7.18 and a beta of 1.33.
In other news, Director Henry Ward Wolff sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.50% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Oppenheimer Asset Management Inc. lifted its position in shares of Portola Pharmaceuticals by 251.2% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 2,047 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Portola Pharmaceuticals by 54.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 1,141 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Portola Pharmaceuticals during the 3rd quarter valued at approximately $178,000. Penbrook Management LLC purchased a new position in shares of Portola Pharmaceuticals during the 4th quarter valued at approximately $209,000. Finally, Sei Investments Co. purchased a new position in shares of Portola Pharmaceuticals during the 3rd quarter valued at approximately $217,000. 86.45% of the stock is currently owned by institutional investors and hedge funds.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.